Accuray Hires General Manager for the EIMEA Region

SUNNYVALE, California, May 18, 2010 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, announced today that Vittorio Puppo, M.D., has joined Accuray
as General Manager of the EIMEA (Europe India Middle East and Africa) region,
effective May 17, 2010.

Prior to joining Accuray, Puppo worked for Covidien, a healthcare device
and supply company, where he served most recently as the EMEA President of
the Surgical Devices division, and as EMEA President of the Imaging division.
Prior to joining Covidien, Puppo worked in a variety of roles at Amersham
Health, an imaging diagnostics and therapy company, which was later acquired
by GE Healthcare. During his career Puppo has worked and lived in Italy, UK,
France and Switzerland.

"Vittorio Puppo's established experience in the healthcare industry
throughout Europe will help us lead teams to continue to grow market share
throughout this region," said Euan S. Thomson, Ph.D., president and chief
executive officer of Accuray Incorporated. "We are very excited to have him
on board and see this as a major step toward the success of our regional
business model and worldwide expansion of the CyberKnife System."

Puppo will report to Accuray's president and chief executive officer, and
will be fully responsible for leading finance, sales, service and marketing
for the EIMEA region.

Presently there are 27 CyberKnife Systems installed throughout EIMEA,
making it the second largest installed base of CyberKnife Systems after the
United States.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to deliver more than 80,000
treatments worldwide and currently 196 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please
visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
qualitative management experience and market acceptance are forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements speak
only as of the date the statements are made and are based on information
available at the time those statements are made and/or management's good
faith belief as of that time with respect to future events. You should not
put undue reliance on any forward-looking statements. Important factors that
could cause actual performance and results to differ materially from the
forward-looking statements we make include: market acceptance of products;
competing products, the combination of our products with complementary
technology; and other risks detailed from time to time under the heading
"Risk Factors" in our report on Form 10-K for the 2009 fiscal year, our
quarterly report on Form 10-Q filed on May 6, 2010, and our other filings
with the Securities and Exchange Commission. The Company's actual results of
operations may differ significantly from those contemplated by such
forward-looking statements as a result of these and other factors. We assume
no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.

Stephanie Tomei, Senior Manager, Marketing Communications, +1-408-789-4234, stomei at accuray.com, or Sancie Nakarat, Manager, EU Marketing, +33-(0)6-81-36-84-34, snakarat at accuray.com